A pharmacological approach to reduce cognitive deficits in psychosis: Targeting of the dopamine D1 receptors.

减少精神病认知缺陷的药理学方法：靶向多巴胺 D1 受体。

• 批准号: 292216
• 负责人: Giros Bruno J
• 金额: $ 49.49万
• 依托单位: CIUSSS de l'Ouest-de-l'Ile-de-Montral-Douglas Hospital
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-09-01 至 2018-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=292216&lang=en
• 关键词: Cognitive Deficits; Pharmacology; Pre-Clinical Models; Schizophrenia

Schizophrenia is a severe brain illness, which reaches more than 1% of the population, independently of the social and cultural background. Today, it is not possible to cure this disease, but only few of the symptoms could be alleviated, thanks to the use

精神分裂症是一种严重的脑部疾病，其发病率超过1%，与社会和文化背景无关。今天，这种疾病不可能被治愈，但由于使用了这种药物，只有少数症状可以得到缓解